182 related articles for article (PubMed ID: 18959062)
1. [Diagnosis and treatment of Gaucher disease in Croatia].
Mrsić M
Lijec Vjesn; 2007 May; 129 Suppl 3():38-42. PubMed ID: 18959062
[TBL] [Abstract][Full Text] [Related]
2. Management of Gaucher disease in a post-communist transitional health care system: Croatian experience.
Mrsić M; Stavljenić-Rukavina A; Fumić K; Labar B; Bogdanić V; Potocki K; Kardum-Skelin I; Rovers D
Croat Med J; 2003 Oct; 44(5):606-9. PubMed ID: 14515422
[TBL] [Abstract][Full Text] [Related]
3. [Gaucher disease: clinical, genetic and therapeutic aspects].
Germain DP
Pathol Biol (Paris); 2004 Jul; 52(6):343-50. PubMed ID: 15261378
[TBL] [Abstract][Full Text] [Related]
4. Gaucher disease: an overview of clinical characteristics and therapy.
Kingma W
J Intraven Nurs; 1996; 19(2):79-82. PubMed ID: 8852167
[TBL] [Abstract][Full Text] [Related]
5. [Gaucher disease: diagnosis and treatment].
Fumić K; Stavljenić-Rukavina A; Mrsić M; Potocki K
Acta Med Croatica; 2004; 58(5):353-8. PubMed ID: 15756799
[TBL] [Abstract][Full Text] [Related]
6. Gaucher disease: from fundamental research to effective therapeutic interventions.
de Fost M; Aerts JM; Hollak CE
Neth J Med; 2003 Jan; 61(1):3-8. PubMed ID: 12688562
[TBL] [Abstract][Full Text] [Related]
7. [Update on Gaucher's disease].
Virgolini L; Silvestri F; Baccarani M
Minerva Med; 1993 Mar; 84(3):81-7. PubMed ID: 8492969
[TBL] [Abstract][Full Text] [Related]
8. Gaucher's disease: a review for the internist and hepatologist.
Niederau C; Häussinger D
Hepatogastroenterology; 2000; 47(34):984-97. PubMed ID: 11020862
[TBL] [Abstract][Full Text] [Related]
9. Miglustat: new drug. In type 1 Gaucher's disease : a slight benefit after imiglucerase therapy.
Prescrire Int; 2005 Oct; 14(79):168-70. PubMed ID: 16285070
[TBL] [Abstract][Full Text] [Related]
10. [Gaucher's disease. Report of 4 cases].
Adarraga Cansino MD; Fernández de la Puebla R; Jiménez Perepérez JA; Pocoví Mieras M; Zambrana García JL; Pérez Jiménez F
Rev Clin Esp; 2002 Dec; 202(12):635-7. PubMed ID: 12459090
[TBL] [Abstract][Full Text] [Related]
11. Consequences of diagnostic delays in type 1 Gaucher disease: the need for greater awareness among hematologists-oncologists and an opportunity for early diagnosis and intervention.
Mistry PK; Sadan S; Yang R; Yee J; Yang M
Am J Hematol; 2007 Aug; 82(8):697-701. PubMed ID: 17492645
[TBL] [Abstract][Full Text] [Related]
12. The clinical course of untreated Gaucher disease in 22 patients over 10 years: hematological and skeletal manifestations.
Piran S; Roberts A; Patterson MA; Amato D
Blood Cells Mol Dis; 2009; 43(3):289-93. PubMed ID: 19793665
[TBL] [Abstract][Full Text] [Related]
13. A new severity score index for phenotypic classification and evaluation of responses to treatment in type I Gaucher disease.
Di Rocco M; Giona F; Carubbi F; Linari S; Minichilli F; Brady RO; Mariani G; Cappellini MD
Haematologica; 2008 Aug; 93(8):1211-8. PubMed ID: 18603565
[TBL] [Abstract][Full Text] [Related]
14. [Gaucher disease--guidelines for diagnosis and management of adult patients].
Merkler M; Simić I; Pećin I; Muacević-Katanec D; Sucur N; Reiner Z
Lijec Vjesn; 2014; 136(5-6):130-3. PubMed ID: 25154180
[TBL] [Abstract][Full Text] [Related]
15. Coagulation abnormalities in type 1 Gaucher disease in children.
Deghady A; Marzouk I; El-Shayeb A; Wali Y
Pediatr Hematol Oncol; 2006; 23(5):411-7. PubMed ID: 16728361
[TBL] [Abstract][Full Text] [Related]
16. Miscellaneous non-inflammatory musculoskeletal conditions. Gaucher disease and bone.
Mikosch P
Best Pract Res Clin Rheumatol; 2011 Oct; 25(5):665-81. PubMed ID: 22142746
[TBL] [Abstract][Full Text] [Related]
17. The long-term international safety experience of imiglucerase therapy for Gaucher disease.
Starzyk K; Richards S; Yee J; Smith SE; Kingma W
Mol Genet Metab; 2007 Feb; 90(2):157-63. PubMed ID: 17079176
[TBL] [Abstract][Full Text] [Related]
18. The clinical and demographic characteristics of nonneuronopathic Gaucher disease in 887 children at diagnosis.
Kaplan P; Andersson HC; Kacena KA; Yee JD
Arch Pediatr Adolesc Med; 2006 Jun; 160(6):603-8. PubMed ID: 16754822
[TBL] [Abstract][Full Text] [Related]
19. A randomized trial comparing the efficacy and safety of imiglucerase (Cerezyme) infusions every 4 weeks versus every 2 weeks in the maintenance therapy of adult patients with Gaucher disease type 1.
Kishnani PS; DiRocco M; Kaplan P; Mehta A; Pastores GM; Smith SE; Puga AC; Lemay RM; Weinreb NJ
Mol Genet Metab; 2009 Apr; 96(4):164-70. PubMed ID: 19195916
[TBL] [Abstract][Full Text] [Related]
20. The effect of enzyme replacement therapy on bone crisis and bone pain in patients with type 1 Gaucher disease.
Charrow J; Dulisse B; Grabowski GA; Weinreb NJ
Clin Genet; 2007 Mar; 71(3):205-11. PubMed ID: 17309642
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
